The UK implemented the biggest overhaul of clinical trials rules in 20 years, with new regulations taking effect April 28. The changes aim to reduce timelines for approvals and introduce a lower-risk category of trials that can be assessed automatically within 14 days. A central mechanism is the Combined Review, allowing sponsors to submit one application to the MHRA for regulatory review and the Health Research Authority for ethics review managed through ethics committees. The policy shift is designed to cut back-and-forth during trial start-up, potentially affecting timelines for investigator sites and the operational burden on sponsors. For biotech developers, the update signals continued regulatory movement toward faster, more modular oversight aligned to risk profiles.